Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,608 public trials 494 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

NCT02159365

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Acrc/Arizona Clinical Research Center, Inc. Tucson, Arizona, United States
  • Highland Oncology Group Fayetteville, Arkansas, United States
  • Comprehensive Blood And Cancer Center Bakersfield, California, United States
  • California Cancer Associates for Research and Excellence Encinitas, California, United States
View all 29 locations
View Trial Details
Completed

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

NCT02811822

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Vejle Hospital Vejle, Denmark
  • Medizinische Klinik/Abt. Innere Medizin V Heidelberg, Germany
  • Cork University Hospital, Wilton Cork, Ireland
  • Beaumont Hospital Dublin, Ireland
View Trial Details
Completed

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211

Conditions
Blood Protein Disorders, Breast Cancer, Breast Diseases, +45 more
Locations
  • Regional Medical Center Anniston, Alabama, United States
  • Providence Cancer Center at Providence Hospital Mobile, Alabama, United States
  • Providence Cancer Center Anchorage, Alaska, United States
  • Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital Fairbanks, Alaska, United States
View all 453 locations
View Trial Details
Completed

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

NCT00153920

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Emory Winship Cancer Institute Atlanta, Georgia, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

NCT01008462

Conditions
B-Cell Prolymphocytic Leukemia, Blood Protein Disorders, Cardiovascular Diseases, +51 more
Locations
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
  • Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Completed

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

NCT01830816

Conditions
Advanced Solid Tumors, Blood Protein Disorders, Cardiovascular Diseases, +13 more
Locations
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
  • Illinois Cancer Care Peoria, Illinois, United States
  • University of Kansas Cancer Center, Clinical Research Center Fairway, Kansas, United States
  • University of Maryland Baltimore, Maryland, United States
View Trial Details

Related conditions